FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm

The FDA has expressed openness to Ipsen’s post-hoc analysis supporting its fibrodysplasia ossificans progressive candidate palovarotene, which will be discussed by an advisory committee on Wednesday.